Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Congratulations to Professors Sallie Lamb and Alan Silman on being appointed to serve on assessment sub-panels for the next Research Excellence Framework (REF) 2021.

The REF assesses the quality and impact of research in UK higher education institutions and determines their core funding.

The process is structured in two phases, the criteria phase taking place this year and the assessment phase, which will commence in late 2020 and continue throughout 2021. The latter will involve the full assessment of submissions made by institutions.

Sallie Lamb, Kadoorie Professor of Trauma Rehabilitation and Director of the Centre for Statistics in Medicine at NDORMS is an interdisciplinary advisor for sub-panel 3 (Allied Health Professions, Dentistry, Nursing and Pharmacy). This is a new role introduced for REF 2021.

Speaking of the appointment, Professor Lamb said: "I am looking forward to contributing to the development of new and important perspectives in the REF. Team science and excellence in inter-disciplinary research will be at the core of innovation and University research cultures of the future."

Professor of Musculoskeletal Health at NDORMS, Alan Silman will serve on sub-panel 2 (Public Health, Health Services and Primary Care). Professor Silman has supported the previous three exercises, both as chair and vice-chair of sub-panels and brings a lot of experience to the assessment team.

"My previous experience has provided substantial insights into how research is evaluated, given the number of different dimensions of assessment. Weighing up the contribution of the novelty of the question, the complexity of the methods and the value of the actual results is never easy. Chairing a previous epidemiology panel was a particular challenge given our desire that the assessment exercise should follow the same ideals of freedom of bias and reproducibility that should underscore any robust epidemiological study!", said Professor Silman.

Chairs and members of the main panels and sub-panels were appointed by the four UK higher education funding bodies following an open nominations process by subject associations and other organisations with an interest in research. Over 4,000 nominations were made for roles across the four main panels and the 34 sub-panels.

The panel members include leading researchers and individuals with expertise in the wider use and benefits of research, as well as members with an international perspective on the main panels.

You can see the full panel and sub-panel membership here.

About the REF

REF2021

See the full panel and sub-panel membership here

Similar stories

Professor Michael Dustin appointed new Chair in Molecular Immunology

A generous gift from the Kennedy Trust for Rheumatology Research has enabled the creation of a new Chair in Molecular Immunology at the University of Oxford.

Empowering data science for single-cell analysis in Zimbabwe

An innovative computational biology training module was launched in November 2022 at the African Institute of Biomedical Science and Technology (AiBST) in Harare, Zimbabwe, where MSc students were trained in single-cell RNA sequencing data analysis.

T-cell coreceptors are well endowed—with kinases!

The kinase occupancy of CD4 and CD8 coreceptors is high, according to a new study published in PNAS.

Two prestigious Hunterian Professorships awarded to NDORMS researchers

Conrad Harrison and Tom Layton have both been awarded Hunterian Professorships for 2022 by the Royal College of Surgeons of England

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

Patients like me

What can patients learn from the experiences of people like them who’ve already had a hip replacement? A new tool called ‘Patients like me’ helps answer some of the questions about pain, complications and how long the prosthesis might last.